https://tbk1ikkin1inhibitor.co....m/high-sensitivity-c
Beginning in 2003, the test included 787 evaluable customers. The median overall follow-up associated with customers ended up being 13.5 many years (range three months to 16.7 years). Based on intention-to-treat analyses, at 15 years, overall and progression-free survival were similar across hands 85%, 83%, 80%, and 82% and 84%, 87%, 79%, and 79% for the IM 400 mg (N = 223), IM 600 mg (N = 171), IM 400 mg + AraC (N = 172), and IM 40
Like
Comment
Share
